The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. | The stars have aligned for Bristol Myers Squibb ...
Pharmaceutical Technology on MSN
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.
With the launch of a new branded initiative, Bristol Myers Squibb is crafting a recipe for both ramping up its Cobenfy rollout and boosting schizophrenia awareness and education. | With the launch of ...
This week, BMS announced a 15-year virtual power purchase agreement (VPPA) with National Grid Renewables for 145 megawatts (MW) of solar at the Texas-based Blevins Project. Combined with the 15-year ...
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...
Beyond the Skyline is a podcast and video interview about economic development, real estate and construction in Minnesota.
The latest information from the National Intellectual Property Administration shows that Hefei Shanhai Semiconductor Technology Co., Ltd. applied for a patent titled "Battery Management System Fault ...
The ink is dry and the keys to a former Bristol Myers Squibb production facility in East Syracuse, New York, have been handed over to Lotte Biologics. The handover was completed Jan. 1, putting a cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback